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biomarker-guided patient selection
Ruud Boessen1*, Hiddo J Lambers Heerspink2, Dick De Zeeuw2, Diederick E Grobbee1, Rolf HH Groenwold1
and Kit CB Roes1Abstract
Background: In many therapeutic areas, individual patient markers have been identified that are associated with
differential treatment response. These markers include both baseline characteristics, as well as short-term changes
following treatment. Using such predictive markers to select subjects for inclusion in randomized clinical trials could
potentially result in more targeted studies and reduce the number of subjects to recruit.
Methods: This study compared three trial designs on the sample size needed to establish treatment efficacy across
a range of realistic scenarios. A conventional parallel group design served as the point of reference, while the
alternative designs selected subjects on either a baseline characteristic or an early improvement after a short active
run-in phase. Data were generated using a model that characterized the effect of treatment on survival as a
combination of a primary effect, an interaction with a baseline marker and/or an early marker improvement. A
representative scenario derived from empirical data was also evaluated.
Results: Simulations showed that an active run-in design could substantially reduce the number of subjects to
recruit when improvement during active run-in was a reliable predictor of differential treatment response. In this
case, the baseline selection design was also more efficient than the parallel group design, but less efficient than
the active run-in design with an equally restricted population. For most scenarios, however, the advantage of
the baseline selection design was limited.
Conclusions: An active run-in design could substantially reduce the number of subjects to recruit in a randomized
clinical trial. However, just as with the baseline selection design, generalizability of results may be limited and
implementation could be difficult.
Keywords: Clinical trial designs, Biomarkers, Baseline selection, Active run-inBackground
Clinical trials are increasingly extensive and complex
[1,2]. They account for the bulk of time and money
invested into drug development [3-5]. To assure the effi-
cient and timely arrival of new and affordable drugs, it is
therefore essential to explore and implement innovative
approaches to the design of clinical trials [6,7].
In many therapeutic areas, prognostic research has
identified subject characteristics that are predictive of fu-
ture clinical outcomes or favorable/unfavorable treatment
response [8,9]. These characteristics can be categorized* Correspondence: ruud.boessen@TNO.nl
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unless otherwise stated.as prognostic or predictive markers [10,11]. Prognostic
markers are associated with future clinical outcomes, ir-
respective of treatment status, while predictive markers
predict the response to treatment. Baseline albuminuria
is an example of a prognostic marker that is associated
with renal and cardiovascular outcomes, while unrelated to
the response to angiotensin receptor blockers [12]. On the
other hand, early albuminuria reduction after a relatively
short duration of exposure to treatment is a predictive
marker, proven to be associated with differential treatment
response on long-term renal and cardiovascular endpoints
in randomized clinical trials [13-15].
Information on markers associated with improved long-
term treatment outcomes could be of use in improving the
efficiency of clinical trials [16]. Predictive markers enablel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fect of treatment (as compared to control) is particularly
beneficial. Restricting randomization to this subgroup
could reduce the sample size requirements needed to es-
tablish treatment benefit.
In this paper we distinguish selection using a baseline
marker from selection on short-term changes that follow
treatment. The former is applied in a baseline selection
design (BSD), whereby only a selection of the recruited
population (for example, those within a predefined range
on the baseline marker) is randomized at baseline. Selec-
tion on short-term marker changes is applied in an
active run-in design (ARD) whereby all the recruited sub-
jects initially receive treatment, and only those with a
predefined minimum improvement are subsequently se-
lected for random allocation to treatment or control. In
this case, improvement on the marker during active run-
in is used as a predictive marker to guide subject selec-
tion for the randomized phase. This design has some
resemblance to a randomized withdrawal design, in which
subjects are all treated with the experimental treatment
until response or recovery, are subsequently randomized
to treatment or control and then followed for a clinical
outcome (for example, a relapse). However, in the present
active run-in design, the initial period is much shorter
and only needed to observe a (minimum) response on a
marker to guide selection.
Both the BSD and the ARD intend to increase study
effect size and reduce its sample-size requirements.
However, both designs do so by randomizing only part
of the recruited population. Therefore, the number of
subjects to recruit will be larger than the number to ac-
tually randomize. As a result, it is not evident upfront
whether the BSD and ARD are more or less efficient
than a conventional parallel group design (PGD) in which
no selection is applied. Moreover, selection based on a pre-
dictive marker restricts the population to which the study
results apply, and thus limits generalizability.
This study uses statistical simulations to compare the
PGD, BSD and ARD on sample-size requirements and
the generalizability of study results. A range of realis-
tic scenarios are evaluated, including a scenario based
on empirical data from two clinical trials that assessed




In both PGD and BSD, subjects are randomized to treat-
ment or placebo at baseline and followed up until either
the clinical endpoint or the end of the study. In PGD,
the study population consists of a random sample from
an unrestricted patient population. In BSD, the study
population is restricted to subjects with a baseline valueon a predictive marker that exceeds a predefined cutoff.
Hence, only a fraction of the subjects who would have
been enrolled in the PGD are actually randomized in the
BSD. In ARD, all subjects start the study on active treat-
ment and only those for whom improvement on the
marker outcome after run-in exceeds a predefined min-
imal cutoff value are randomized to treatment or pla-
cebo in the second study stage. They are then followed
up until either the clinical endpoint or the end of the
study.
In both BSD and ARD, the proportion of the enrolled
population that continues into the randomized study
stage can be denoted by P, and is dependent on a selec-
tion criterion c. Supposing that both a lower baseline-
marker level and a greater improvement on the marker
during active run-in are associated with a reduced inci-
dence rate of the endpoint in the randomized study
stage. In that case, when the absolute value of c is large,
P is small since only few subjects meet the selection cri-
terion. Furthermore, the observed effect of treatment on
the endpoint will be relatively large in the randomized
population, but the fraction of the total population to
which these findings apply is reduced and generalizability
is limited. Conversely, when c is smaller, p is larger and the
observed effect in the randomized population is relatively
small, however generalizability improves. It is important to
note that the value of c is a design parameter that should
always be defined before the study starts to control the
type-I error rate of subsequent tests. In PGD, there is no
selection criterion and all recruited subjects are also ran-
domized for follow-up.
Simulations
A simulation study was conducted to assess the sample-
size requirements of PGD (NPGD), BSD (NBSD), and ARD
(NARD). In all designs, subjects were randomized in a 1:1
ratio of treatment to control, either at baseline (PGD and
BSD) or after an active run-in stage (ARD).
A single, large dataset (representing 100,000 subjects)
was generated. Included in this dataset was the treat-
ment status in the first (before randomization) and second
(after randomization) study stage (T1 and T2, respectively
with 0 representing placebo and 1 representing active treat-
ment), and the marker level at baseline (A0) and after the
end of the run-in stage (A1). Treatment status was inde-
pendent of marker levels.
For PGD and BSD, the treatment status of a subject
was the same in the first and second study stage (T1 =T2).
For ARD, all subjects were treated in the first stage (T1 = 1)
and randomized in the second. A0 and A1 were generated
as follows: first, two series were generated from a multi-
variate normal distribution ~N(3,1)) with correlation r.
The first series represented A0, and A1 was derived as the
second series minus Δ (the assumed mean improvement
Table 1 Parameters and parameter values that define the
various simulation scenarios
Scenario r Δ β1 β2 β3 β4
IA 0.7 0.5 0.0 0.0 0.0 −0.6
IB 0.7 0.5 0.0 0.0 −0.1 0.0
IC 0.7 0.5 0.0 0.0 −0.1 −0.6
IIA 0.7 0.5 −0.3 0.0 0.0 −0.6
IIB 0.7 0.5 −0.3 0.0 −0.1 0.0
IIC 0.7 0.5 −0.3 0.0 −0.1 −0.6
IIIA 0.7 0.5 0.0 0.5 0.0 −0.6
IIIB 0.7 0.5 0.0 0.5 −0.1 0.0
IIIC 0.7 0.5 0.0 0.5 −0.1 −0.6
r is the correlation between A0 and A1. Δ is the assumed mean improvement
on the marker on treatment in the first design stage. β1 is the primary effect
of treatment in the second stage, β2 is the main effect of baseline marker
level, β3 is the treatment status by baseline marker level interaction and β4 is
the treatment status by first-stage marker improvement interaction.
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improvement on the marker was assumed among subjects
on placebo, and so for this group Δ = 0.
Endpoint-free survival times were generated using the
method described by Bender et al. [17]. First, a linear
predictor (lp) was defined by:
lp ¼ β1T2 þ β2A0 þ β3T 2A0 þ β4T 2 A0−A1ð Þ ð1Þ
In which β1 represented the primary effect (the effect
that was not mediated through the marker) of treatment
in the second stage, β2 the main effect of baseline marker
level (the prognostic part of the baseline marker), β3 the
treatment status by baseline marker level interaction (the
predictive part of the baseline marker), and β4 the treat-
ment status by first-stage marker improvement interaction
(predictive part of change on the marker). Equation 1 can
be rewritten into:
lp ¼ β1 þ β3A0 þ β4 A0−A1ð Þ
 
T 2 þ β2A0 ð2Þ
to show that the effect of treatment status in the second
stage is a combined function of β1, β3 and β4.
Based on the linear predictor, endpoint-free survival
times (S) were generated using:
S ¼ − log Uð Þ
λ0exp lpð Þ ð3Þ
where λ0 is the baseline hazard and U is a random num-
ber generated from the uniform distribution U(0,1).
The total follow-up duration was truncated at 100
units of time for all three designs. The run-in period was
set to comprise 12 percent of the total study duration
(corresponding to about 3 months in a study with a
2 year total follow-up duration). Hence, while the total
duration of the different designs was equal, the duration
of the randomized study stage was 12 percent shorter
for ARD as compared to PGD and BSD. Subjects who
experienced an event during the active run-in stage in
ARD were excluded from analysis, thus in principle po-
tentially reducing the efficiency of ARD in terms of sam-
ple size as compared to the other designs. In practice
this would typically result in a small number of subjects
excluded, since the active run-in phase is usually only a
relatively small part of the total study duration.
The performance of the three designs was evaluated
across three sets of scenarios which are presented in
Table 1. Within each set, multiple combinations of β3
and β4 (the predictive parts of the marker and change
on the marker during run-in) were defined, and the sets
differed in the values for β1 and β2 (primary treatment
effect and the prognostic part of the marker). In
addition, the sets differed in the value for the baseline
hazard (λ0), which was chosen to result in equal eventrates for the PGD placebo arm across the different
scenarios.
For every scenario a separate dataset was generated.
From this dataset, only subjects with A0 > cA0 (subjects
for whom the marker level at baseline exceeded the
threshold CA0) were randomized in the BSD, and only
those with A0-A1 > cA0-A1 (subjects for whom marker im-
provement exceeded the threshold cA0-A1) were random-
ized in the ARD. The values for cA0 and cA0-A1 were
chosen to result in P, representing a designated percent-
ile (100, 90, and so forth, down to 10 percent of the total
population). The cutoff values were based on the entire
unselected population. Obviously no subject selection
was applied in the PGD (P = 1.0).
For every value of P (1.0 - 0.1), the number of subjects
to include to significantly establish treatment efficacy in
the corresponding stratum was estimated based on a
log-rank test with 80 percent statistical power and a
nominal type-I error rate of 5 percent, two-sided. The
process of generating a dataset and estimating the re-
quired sample size for the various strata was repeated
100 times, and estimates were averaged across replica-
tions in order to reduce random simulation error. The
resulting value represented the number of subjects to be
randomized, and was multiplied by the inflation factor
1/P in order to obtain the number of subjects to be re-
cruited. For the PGD the same steps were performed,
but since no subject selection was applied, the number
of subjects to be randomized equaled the number to be
recruited.
The data simulated for subjects in a selected stratum
could be used to derive an (extrapolated) overall effect-
size estimate (hazard ratio) for the overall unrestricted
population based on the regression model, with parame-
ters estimated from the data in that particular replication.
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design is carried out and a treatment effect for the total
population is estimated from the results of that specific
trial. Obviously, this overall effect-size estimate becomes
less precise when it is derived from an increasingly re-
stricted subgroup. We evaluated the precision of these esti-
mates for the various strata in both ARD and BSD by
estimating the effect-size for the overall population from
the various strata and replicating this process 1000 times.
Empirical example of antihypertensive trials with
diabetic patients
We evaluated three designs for a scenario derived from
the data of two empirical studies. The Reduction in
End Points in NIDDM (noninsulin-dependent diabetes
mellitus) with the Angiotensin II Antagonist Losartan
(RENAAL) study and the Irbesartan Diabetic Nephropathy
Trial (IDNT) were both multinational, randomized,
double-blind trials with a renal endpoint (development of
end-stage renal disease or death from any cause), con-
ducted in patients in advanced stages of diabetic nephrop-
athy [18,19]. The RENAAL and IDNT trials involved 1513
and 1715 patients respectively. In the RENAAL trial,
patients received losartan (either 50 or 100 mg/day) or
placebo. In the IDNT trial, patients received irbesartan
(300 mg/day), amlodipine (10 mg/day) or a matched pla-
cebo. Both trials were designed to compare an angiotensin
receptor blocker based antihypertensive regimen with a
conventional blood pressure lowering regimen. To this
end, blood pressure was targeted to achieve a blood pres-
sure goal of less than 140/90 mmHg. If the blood pressure
target was not achieved, additional antihypertensive agents
(but not ACE-inhibitors or angiotensin receptor blockers)
were allowed throughout the study. The average follow-up
time was 3.4 years for the RENAAL study and 2.6 years
for IDNT. Several clinical and laboratory characteristics
were assessed at regular intervals during the trials. These
included a measurement of albuminuria at baseline and
after 3 months of follow-up. For the present study, the
data from the losartan and irbesartan arms were pooled
into a single active-treatment group and compared to the
pooled data from both placebo arms. For the purpose of
analysis, the amlodipine arm (567 subjects) of the IDNT
trial was excluded. The distribution of albuminuria levels
was first normalized by applying a log-transformation, and
then standardized and shifted three units upward, in order
to allow for comparisons with the results from our simula-
tions. Follow-up was truncated at 750 days (approximately
2 years), again to allow for comparisons.
The data were fitted to the model represented by
Equation 1, in order to estimate the effects of treatment,
biomarker levels, and their interactions on the outcome.
The other parameters used in the simulations (r, Δ,
and λ0) were also derived from the empirical data.The resulting scenario was evaluated using the simula-
tion approach described above. This allowed us to deter-
mine the number of patients to recruit for the PGD and
for the various strata in the ARD and BSD for this par-
ticular empirical example.
Results
Simulation results for the first set of scenarios are pre-
sented in Figure 1. These scenarios did not include a pri-
mary effect of treatment unrelated to baseline marker
level or short-term marker improvement (β1 = 0), nor an
association between baseline marker level and outcome
incidence (β2 = 0). In other words, baseline marker level
was not included as a prognostic factor for survival, and
the full effect of treatment as compared to placebo could
be predicted from baseline marker levels or early marker
improvements during the run-in stage.
In scenario IA, the effect of treatment was fully
expressed as part of the interaction with early marker
improvement (β3 = 0, β4 ≠ 0). In this case, both ARD and
BSD had the potential to reduce sample-size require-
ments in comparison to PGD. For ARD in particular, the
increase in treatment effect from the unselected popula-
tion to more restricted patient strata outweighed the loss
of efficiency due to the exclusion of subjects that did
not meet the selection criteria. With optimal restriction
(P = 0.5), ARD required a little under one third of the
sample size that was required with PGD. Further restric-
tion reduced the comparative efficiency of ARD, since
the further increase in treatment effect no longer out-
weighed the exclusion of subjects after the run-in stage.
It should be noted that when P = 1, ARD required
slightly more subjects than either PGD or BSD (a general
picture seen in all evaluated scenarios), as events during
the active run-in stage were excluded in the analysis, lead-
ing to a slightly smaller total event rate in ARD. BSD was
also more efficient than PGD as the higher baseline
marker levels were correlated with larger marker improve-
ment and thus a larger effect on survival. As a result, sub-
jects in the more restricted strata generally displayed a
larger marker improvement and hence a stronger effect of
treatment. At the optimal level of restriction (P = 0.7),
BSD was about 30 percent more efficient than PGD, but
still less efficient when compared to ARD.
When the effect of treatment was fully expressed as
part of the interaction with baseline marker levels (β3 ≠ 0,
β4 = 0; scenario IB), neither BSD nor ARD were more
efficient than PGD for any value of P. In this case, the lar-
ger treatment effect in more restricted strata was can-
celled out by the increasing proportion of subjects that
were excluded after selection. ARD was less efficient than
BSD as improvement on the marker during run-in was
only partly related to baseline marker level, and hence to
an increase in effect size with more restricted strata. In
AB C
Figure 1 Improvement rates in the number of patients to recruit for ARD and BSD as compared to PGD under scenarios IA-C. Positive
improvement indicates smaller sample sizes and thus higher efficiency. The sample size requirements for the parallel group design were 1386,
800 and 318 for scenario IA-C, respectively. ARD, active run-in design; BSD, baseline selection design; PGD, parallel group design.
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had a higher baseline marker level to start with, and
while improvement in the marker in itself was unrelated
to survival in this scenario (β4 = 0), baseline marker level
was not (β3 ≠ 0).
When the treatment effect could be predicted by the
baseline marker level as well as short-term marker im-
provement (β3 ≠ 0, β4 ≠ 0; scenario IC), ARD and BSD
had some potential to increase efficiency when com-
pared to PGD, but considerably less than when the treat-
ment effect was only included as part of the interaction
with marker improvement (scenario IA). For ARD, the
increased treatment effect in more restrictive strata still
outweighed the exclusion of subjects after run-in, but
only up to a certain degree of restriction. Further restric-
tion (P < 0.2) dramatically reduced its efficiency relative
to PGD. The largest increase in efficiency of ARD corre-
sponded to approximately 25 percent fewer subjects
than PGD. For BSD, the maximum efficiency gain was
only 10 percent.Figure 2 shows the results for the second set of scenar-
ios which all included a primary effect of treatment
(β1 ≠ 0), which meant that part of the long-term treat-
ment effect was unrelated to baseline marker level or
short-term marker improvement. These scenarios did
not include an association between baseline marker level
and outcome (β2 = 0). In this case, sample sizes were re-
duced overall since the total effect of treatment was a
combined function of β1, β3 and β4 (Equation 2), and
therefore larger than in the scenarios of the first set. In
general, the results showed the same patterns as ob-
served for the first set, but the potential for an efficiency
gain (for ARD and BSD as compared to PGD) was re-
duced over the whole range of P. This resulted from the
fact that the relative difference in treatment effect asso-
ciated with an increase in β3 and/or β4 was smaller.
Figure 3 presents the results for the third set of sce-
narios, which are very similar to those for the first set.
Scenarios IIIA-C included an association between base-
line marker level and outcomes (β2 ≠ 0), but no primary
AB C
Figure 2 Improvement in the number of patients to recruit for ARD and BSD as compared to PGD under scenarios IIA-C. Positive
improvement indicates smaller sample sizes and thus higher efficiency. The sample size requirements for PGD were 298, 228 and 146 for scenario
IIA-C, respectively. ARD, active run-in design; BSD, baseline selection design; PGD, parallel group design.
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baseline marker level or short-term marker improvement
(β1 = 0). Equation 2 already demonstrates that β2 had no
influence on the treatment effect size, but instead resulted
in an overall increase in event rate (for both the control
and the treatment group), which was corrected for by a
lowering of the baseline hazard.
Figure 4 shows the estimates of the effect size in the
full (unselected) patient population as derived from the
various patient strata in ARD and BSD. As expected,
the imprecision of these effect-size estimates increased
when they were derived from increasingly restricted,
and thus smaller strata. In other words, there is an in-
creased risk that the extrapolated effect-size estimate
for the unselected population is biased when it is de-
rived from increasingly restricted strata. The impreci-
sion is larger for BSD than for ARD, because the time
between patient selection and end of follow-up was
shorter in ARD.Finally, Figure 5 shows the results for the scenario that
was derived from empirical data. This scenario was char-
acterized by the following parameters: β1 = -0.25 (P =
0.51), β2 = 1.10 (P < 0.01), β3 = 0.05 (P = 0.61), β4 = -0.49
(P < 0.01), r = 0.79, Δ = 0.32, and λ0 = 7.7e
−5. These results
indicate that baseline albuminuria is a strong prognostic
factor for endpoint-free survival, but not significantly as-
sociated with differential treatment response, while early
improvement in albuminuria is significantly associated
with differential response to treatment. In addition, the
primary effect of treatment was small and not significant.
Clearly, these estimates were derived from a model that
may not have been the most adequate representation of
these data. As a result, they should be interpreted with
care.
The simulation results indicate that BSD does not have
large potential to increase efficiency when compared to
PGD. In contrast, ARD did have the potential to increase
efficiency. With an unselected population (P = 1.0) the
AB C
Figure 3 Improvement in the number of patients to recruit for ARD and BSD as compared to PGD under scenarios IIIA-C. Positive
improvement indicates smaller sample sizes and thus higher efficiency. The sample size requirements for the PGD were 900, 692 and 236 for
scenario IIIA-C, respectively. ARD, active run-in design; BSD, baseline selection design; PGD, parallel group design.
Figure 4 Estimates of the hazard ratio for the overall (unrestricted) population as derived from the various patient strata in ARD and
BSD. Each circle represents the estimate from a single replication. The white dot is the average estimate over 1000 replications. ARD, active run-in
design; BSD, baseline selection design.
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Figure 5 Sample-size requirements for ARD, BSD and PGD under the scenario based on empirical data from two clinical trials that
assessed the efficacy of antihypertensive treatments in diabetic patients. ARD, active run-in design; BSD, baseline selection design; PGD,
parallel group design.
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PGD, but with optimal restriction (P = 0.5) the advantage
was about 35 percent (Figure 5).
Discussion
This study evaluated the sample-size requirements (the
number of subjects to be recruited) to establish treat-
ment efficacy for three study designs across a range of
realistic scenarios. These scenarios characterized the ef-
fect of treatment on endpoint-free survival as a combin-
ation of an interaction with a baseline marker and/or
short-term marker improvements in addition to a pri-
mary effect that was unrelated to both. The designs
include: a conventional PGD with an unselected study
population, a BSD that is similar to the PGD, but ran-
domizes only a selection of the recruited population
based on a predictive baseline marker, and 3) an ARD that
exposes all subjects to a short treatment run-in phase and
randomizes only those with a predefined improvement on
the marker during the run-in stage.
Findings indicated that ARD is generally the most effi-
cient design to establish treatment efficacy when short-
term improvements during the active run-in stage are
a reliable predictor for the long-term effect of treat-
ment on survival. In the presence of a reliable base-
line predictor or a primary treatment effect (unrelated
to any observed marker value) the advantage of ARD
decreased.
When short-term improvements were strongly related
to long-term survival, BSD had an advantage over PGD
as higher baseline marker levels were correlated with lar-
ger short-term improvements. When only the baseline
marker level in itself was predictive of treatment efficacy,
the observed effect in BSD was larger than in PGD, butdid not result in a more efficient design as a portion of
the recruited population was excluded in the selection.
In none of these cases was there any meaningful advan-
tage of baseline selection.
An additional scenario was evaluated that was based
on empirical data from two diabetes trials. Here, baseline
albuminuria was a prognostic biomarker for endpoint-
free survival, and short-term reduction in albuminuria
after treatment was predictive of differential treatment
response on survival. In this scenario, ARD had the po-
tential to reduce sample-size requirements as compared
to PGD with up to 35 percent. This efficiency advantage
would have been achieved by randomizing only the top
50 percent of the recruited population with the largest
early reduction in albuminuria during the run-in phase.
While in this example patient selection was based on a
predictive biomarker, it could also be based on a gen-
omic marker [20] or a risk score from a prognostic
model [21]. The use of genomic-based predictive bio-
markers is an area of great research interest in oncology.
The discovery of genes that have been proven to be of
clinical relevance such as the Her2/neu gene in breast
cancer and epidermal growth factor 1 (EGFR1) in non-
small cell lung cancer has intensified interest in this
area. Mutations in these genes can be used for baseline
patient selection who are more susceptible for interven-
tion. It has been shown that Her2/neu positive tumors
are more aggressive. Patients with Her2/neu overex-
pressing tumors benefit from trastuzumab, a monoclonal
antibody against the Her2/neu receptor. It should be
noted that not all patients with positive Her2/neu status
respond to trastuzumab, which may be due to primary
or acquired resistance against trastuzumab [22,23]. With
regards to EGFR1, two small molecule tyrosine kinase
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available. Emerging data demonstrate that among non-
small-cell lung carcinoma patients mutations in the tyro-
sine kinase domain (exons 18, 19 and 21) are predictive
of the response to gefitinib and erlotinib [24,25]. Muta-
tions in the tyrosine kinsase domain stimulate EGFR1
signaling, thereby increasing susceptibility to EGFR1 in-
hibitors and amplifying clinical responsiveness. More ex-
amples about genomic predictive markers in oncology
are reviewed elsewhere [26]. With respect to enrichment
design, a recent study has suggested that among lung
cancer patients, selecting responder patients after two
cycles of chemotherapy in combination with histological
scoring may predict long-term survival benefit [27]. Fur-
ther studies are required to confirm these findings. An
example of predictive short-term change with treatment
includes the lowering of LDL cholesterol and the effect
of lipid-modifying therapies on the risk for cardiovascu-
lar events [28].
Both BSD and ARD apply selection based on an indi-
vidual patient measure that is associated with differential
treatment response. This measure is obtained either at
baseline (BSD) or after a relatively short exposure to
treatment in an active run-in stage (ARD). In statistical
terms, there is an interaction between this measure and
the long-term effect of treatment on the outcome. In
biological terms, there may be an undisclosed underlying
mechanism to explain the interaction. As a result, every
conceivable gain in efficiency (with BSD or ARD) is as-
sociated with a reduction in the generalizability of the
trial results. This results from the fact that the selected
and randomized subgroup is unrepresentative of the en-
tire patient population. Moreover, it becomes increas-
ingly difficult to extrapolate the observed effect to the
overall population when selection becomes increasingly
restrictive.
As a result, findings from BSD and ARD apply primarily
to the selected patient subgroup and cannot be readily ex-
trapolated to a broader population without running the
risk of introducing bias. This complicates general state-
ments on the efficacy of the investigated drug and illus-
trates an important concern regarding the use of these
designs in confirmatory clinical trials. In a sense, both
BSD and ARD generate a substantial amount of “missing
data”, which is to say, information on the (long-term) effi-
cacy and safety of the drug that will be missing for the
deselected population. In this respect, ARD has an advan-
tage over BSD in that it collects considerable information
on the short-term effects of the experimental treatment
during the run-in phase. Both ARD and BSD are likely
most beneficial in situations where a meaningful effect of
treatment in the total population is unlikely, but valid
markers are available to reliably identify patient subgroups
where benefit from treatment is improved.There is also a difference in the clinical implications of
the results from both designs. BSD reflects a situation
whereby prescription of the drug is restricted to patients
with a specific baseline characteristic that is related to
its outcome, which is something that often occurs in
clinical practice as well. ARD, on the other hand, reflects a
situation where the drug is initially prescribed to everyone
and early improvement on a measurable marker decides
whether treatment is continued or aborted.
The practicality of BSD and ARD is obviously dependent
on the availability of a valid and reliable predictive marker
that can identify a patient subgroup most likely to benefit
from treatment. Appropriate markers are those on the
causal path from treatment to effect and are preferably
identified in earlier (pre-clinical) studies. If long-term effi-
cacy of the investigated treatment is unrelated to an avail-
able marker, the enrollment of only marker-positive
subjects may slow down recruitment, increase expenses,
and unnecessarily limit the size of the indicated popula-
tion. As to be expected, both ARD and BSD were also
found to be less efficient than PGD in this scenario
(results not shown). If the investigated treatment truly
benefits a specific subgroup but the marker used for selec-
tion is unfit to accurately identify that group, a beneficial
treatment could mistakenly be abandoned. It is however,
notoriously difficult to identify genuine predictors of dif-
ferential treatment response. Such evidence is usually ac-
cumulated slowly from secondary analyses of existing
trials and meta-analyses.
In the current study, data were generated using a fairly
straightforward model that divided the total effect of
treatment on long-term survival into three components
(a primary effect, an interaction with a baseline marker
and an interaction with short-term improvement on
treatment), and in addition included the baseline marker
as a prognostic marker for survival (unrelated to treat-
ment status).
When the effect of treatment was fully accounted for
by its interaction with the baseline marker, the increase
in efficiency that resulted from larger effect sizes in
more restricted strata was cancelled out by the exclusion
of recruited subjects after selection. In this case, both
BSD and ARD had very limited potential to increase
efficiency as compared to PGD. This resulted from the
fact that baseline marker levels were linearly associated
with the linear predictor (Equation 1) and exponentially
associated with the treatment vs. control hazard ratio
(Equation 3). Consequently, the additional reduction in
the number to randomize decreased exponentially with
further restriction of the indicated population. When re-
striction was more extreme, the exclusion of subjects
after selection started to outweigh the advantage of larger
effects in the more restricted strata. Under these circum-
stances, BSD was only more efficient than PGD when
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between baseline marker level and treatment status,
which was not included in the evaluated scenarios.
Some consideration regarding our model should be
mentioned. An increase in the prognostic effect of base-
line marker level increased the treatment effect size, and
hence reduced sample-size requirements despite adjust-
ment of the baseline hazard, to result in equal event
rates for the control group as observed in the other sce-
narios. When data were simulated based on a model that
included a prognostic effect of the baseline marker on
survival there was more variation in the individual haz-
ards. This caused some subjects to develop the endpoint
early in the trial, irrespective of their treatment status,
whereas others were very unlikely to experience the
endpoint during the trial. The net effect was that the
probability of the outcome after a certain period of
follow-up was lower among treated subjects compared
to the treated subjects in the simulations based on the
model without the prognostic effect of baseline marker
level on survival.
The model used is fairly flexible and fitted the experi-
mental data well. However, results and conclusions may
not hold to the same extent if a substantially different
model is used. This will particularly be the case if the
underlying proportional hazards assumption does not
apply.
It should also be noted that the improvement in effi-
ciency with BSD and ARD as reported in this study is
relative to a PGD that disregards baseline marker level
and early changes in the marker in response to treat-
ment as a covariate in the analysis of the data. Including
these factors as covariates in the final drug efficacy ana-
lysis would improve the efficiency of the PGD, and
hence reduce the comparative advantage of both ARD
and BSD.
Conclusions
In summary, our results suggest that an ARD can substan-
tially reduce the number of subjects to recruit in a clinical
trial when short-term improvement on the marker during
the run-in phase is a strong and reliable predictor of dif-
ferential treatment response. Under these conditions, BSD
was also potentially more efficient than PGD, but always
less efficient than ARD given equally restricted strata. For
all other scenarios evaluated, no meaningful advantage
was observed for BSD. Generalizability issues may limit
the applicability of ARD and BSD in practice. In addition,
valid markers must be available to reliably identify patient
subgroups with an increased likelihood to eventually bene-
fit from investigational treatment.
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